New hope for esophageal cancer patients after standard treatment fails
NCT ID NCT07530549
First seen Apr 20, 2026 · Last updated May 14, 2026 · Updated 3 times
Summary
This study tests whether a combination of two immunotherapy drugs (Iparomlimab and Tuvonralimab) plus chemoradiotherapy can help people with locally advanced esophageal cancer whose prior chemo-immunotherapy did not work. About 40 adults aged 18-75 will receive the treatment, and researchers will track how long they live without the cancer growing or returning, as well as side effects. The goal is to see if this approach can improve survival and possibly allow surgery later.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCAL ADVANCED ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.